Abstract: The present invention includes a method for diagnosis and treatment and prevention of Alzheimer's Disease comprising obtaining a biological sample from a subject suspected of having Alzheimer's Disease; determining the level of expression of HSP 27, wherein a statistically significant increase in HSP27 protein expression in the sample as compared to a sample from a non-Alzheimer's patient is indicative that the subject has Alzheimer's Disease; and modifying the treatment of the subject as a result of the detection of Alzheimer's Disease by providing the subject with standard therapy or a single vector expressing an A?42 trimer peptide and optionally the addition of an A?42 peptide, which elicits an immune reaction against the A?42 peptide, thereby preventing the accumulation of A?42 peptide and therefore preventing or treating Alzheimer's Disease.

Abstract: Compounds having quinone and quinone analogs useful for pharmaceutical preparations have now been found which inhibit cysteine proteases, in particular, caspases and 3C-cysteine proteases. The cysteine protease inhibitors of the present invention can be identified by their mode of action in disrupting the ability of cysteine proteases and, in particular, caspases to cleave a peptide chain. These compounds are useful in inhibiting cysteine protease or cysteine protease-like proteins and for treating infections diseases or physiopathological diseases or disorders attributed to the presence of excessive or insufficient levels of cysteine proteases.

Abstract: A method for identifying molecules and designing novel pharmaceuticals is disclosed. The disclosed method of novel pharmaceutical design identifies a novel chemical group that triggers a mechanism of action for an identified reaction, thereby avoiding the various structural complexities associated with the application of the structure-based drug design. Additionally, examples of potential therapeutics identified by the mechanism based drug design method are provided.

Abstract: Hybridomas secreting monoclonal antibodies specific for an epitope found in the amino acids of LCGA associated with non-small cell lung carcinoma protein have been found. The monoclonal antibodies produced by these hybridomas can be used in in vivo and in vitro clinical diagnosis of non-small cell lung carcinoma and ovarian carcinoma and as target selective carriers for various anti-tumor agents and radioimaging agents.

Abstract: Hybridomas secreting monoclonal antibodies specific for an epitope found in the amino acids of LCGA associated with non-small cell lung carcinoma protein have been found. The monoclonal antibodies produced by these hybridomas can be used in in vivo and in vitro clinical diagnosis of non-small cell lung carcinoma and ovarian carcinoma and as target selective carriers for various anti-tumor agents and radioimaging agents.

Abstract: The present invention discloses an isolated and purified nucleic acid sequence and corresponding amino acid sequence to a novel protein specific for human lung cancer cells. This gene is expressed at a much higher level in these cells than in normal lung cells, other normal tissues and other tumor cell lines tested. Also disclosed are three additional recombinant forms of this gene and protein, in the first two cases a membrane spanning region is removed and in the third case an amino acid is changed by in vitro mutagenesis.

Abstract: The present invention discloses an isolated and purified nucleic acid sequence and corresponding amino acid sequence to a novel protein specific for human lung cancer cells. This gene is expressed at a much higher level in these cells than in normal lung, other normal tissues and other tumor cell lines tested. Also disclosed are two additional recombinant forms of this gene and protein, in the first case a membrane spanning region is removed and in the second case an amino acid is changed by in vitro mutagenesis. Also disclosed are nucleic acid probes for the detection of lung cancer cells from tissue biopsy and body fluids such as serum, sputum and bronchial washings. A method for expressing the antigen in a host cell and its subsequent use as an immunogen in antibody production for test applications is described. An ELISA test to measure shed antigen present in patient samples as well as an enzyme test to measure activity in specimens also is described.